Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 50Stomach Neoplasms 7Neoplasm Metastasis 5Colorectal Neoplasms 4Uterine Cervical Neoplasms 3HER2-positive Breast Cancer 3Esophageal Neoplasms 3Uterine Neoplasms 2Solid Tumors 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Compliance 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1

Interventions

enzalutamide 33Abiraterone Acetate 29apalutamide 26Prednisone 26Radiotherapy 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 22Radiosurgery 19darolutamide 18Docetaxel 17Gonadotropin-Releasing Hormone 16acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 13gallium 68 PSMA-11 12bicalutamide 12Specimen Handling 12Radiotherapy, Intensity-Modulated 12abiraterone 11Radiation 11pembrolizumab 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Triptorelin Pamoate 8Standard of Care 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × Trastuzumab × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡